partager sur facebook

ICAN Investigation




The ICAN Investigation core is dedicated to clinical phenotyping and clinical research and  provides protocols set-up and implementation, recruitment services, screening and extensive cardiometabolic and environmental phenotyping of clinical trials volunteers for ICAN members and external partners.

ICAN Investigation has built a  Cardiometabolic Phenotyping Platform with benefits from the outstanding potential of ICAN clinical teams for the recruitment of patients with diverse phenotypes and local expertise of ICAN clinicians in CMD.

ICAN Partners such as Clinical Investigation Centre (CIC) Paris-East (Pr. Funck-Brentano), the Human Nutrition Centre of Île-de-France – CRNH (Pr. Oppert) and ACTION, an Academic Research Organization – ARO (Pr. Montalescot) allow to offer all means to conduct clinical research in both pharmaceutical and nutrition sectors.

ICAN Cardiometabolic phenotyping platform provides extensive cardiometabolic and environmental phenotyping of clinical trials volunteers for ICAN members and external partners through 5 Phenotyping Core Labs:


1 – Cardiovascular function Core Lab (supervised by Dr. Hammoudi and Dr. Rosenbaum) to measure heart function and  vascular function using state-of-the-art equipment.

The cardiology team has expertise in morphological and hemodynamic assessment of the heart at rest, as well as, during physical exercise and pharmacological stress (evaluation of ischemia, valvular disease, diastolic stress echo). Coupling ultrasound imaging and cardiopulmonary exercise testing provides a pathophysiological approach to establish diagnosis and prognosis of cardiac diseases. It also offers the possibility to realize centralized qualitative and quantitative analysis and interpretation of echo examinations realized by other centers.


2 – Cardiometabolic Imaging Core Lab (supervised Dr. Redheuil M.D.Ph.D.).

The team has expertise in development of innovative cardiovascular imaging and coordinates and optimizes the use of existing La Pitié Salpêtrière Hospital imaging capacities (centered on the Cardiovascular imaging platform of the Heart Institute under the leadership of Pr. Cluzel and access to ICM and Myology Institutes imaging sequences (3T and 4.7T MRIs)).

His objective is to develop and validate innovative imaging processing and analysis to allow the discovery of new cardiometabolic imaging biomarkers from multimodality imaging (including computed tomography, NMR and ultrasounds) than can be used in patient care.


3 – Physical Activity & Environment Core Lab (supervised by Pr. Oppert).

This Core lab provides state-of-the-art measurements of physical activity, muscle performance and energy expenditure through hood indirect calorimetry, accelerometry-based movement sensors, coupled with GPS technology condition and validated questionnaires (environmental & societal patterns measurement included) evaluated under free-living condition.

The Physical activity Core Lab has expertise in studying impact of physical activity training programs on morbid obesity and has already performed a number of lifestyle interventions in day-to-day practice. All its equipment can handle obese patients


4 – Metabolic Explorations Core Lab (supervised by Pr. Oppert). This Core lab provides state-of-the-art measurements of:

– body composition through a whole range of validated techniques such as plethysmography (BOD POD), impedancemetry, biphotonic absorptiometry (DXA), software development to quantify visceral fat by CT scan and LIMC
– metabolic indicators through evaluation of insulin sensitivity by ambulatory measurement of glycemia, clamps studies and use of stable isotopes
– eating patterns through food intake habits validated questionnaires as well as development of Internet-based tools device for food intake patterns
– night respiratory function through nocturnal ventilory monitoring


5 – Tissue Phenotyping Core Lab (supervised by Pr. Lesnik).

This core lab is dedicated for sample and tissue handling. Tissue & organ inflammation and lipid burden can be determined through development of new image analysis in immunohistochemistry as well as ex vivo assays on tissue explants